VANOBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANOBID (VANOBID).
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
| Metabolism | Vancomycin is primarily excreted unchanged by glomerular filtration, with minimal metabolism. Approximately 80-90% of an administered dose is recovered in urine within 24 hours. |
| Excretion | Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 85-92% bound to albumin. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration. |
| Bioavailability | Oral: 60-80% (first-pass metabolism reduces absolute bioavailability); Topical: 5-15% (systemic absorption depends on application site and skin integrity); Intramuscular: 90-100%. |
| Onset of Action | Oral: 1-2 hours; Topical: 2-4 hours; Intramuscular: 30-60 minutes. |
| Duration of Action | Oral: 12-18 hours; Topical: 6-12 hours (varies with formulation); Intramuscular: 12-24 hours. |
| Molecular Weight | 451.54 |
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
| Dosage form | OINTMENT |
| Renal impairment | GFR 30-50 mL/min: 500 mg every 12 hours; GFR 15-29 mL/min: 500 mg every 24 hours; GFR <15 mL/min: 500 mg every 48 hours. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%. |
| Pediatric use | 5-10 mg/kg/dose orally every 12 hours; maximum 500 mg per dose. |
| Geriatric use | Initiate at lower end of dosing range (250-500 mg every 12 hours) due to age-related renal function decline. |
| 1st trimester | No adequate studies in pregnant women; use only if potential benefit justifies potential risk to fetus. Animal studies have shown teratogenic effects. |
| 2nd trimester | Same as T1; limited data, avoid use unless clearly needed. |
| 3rd trimester | Same as T1; may cause adverse effects in neonate; avoid near term if possible. |
Clinical note
Comprehensive clinical and safety monograph for VANOBID (VANOBID).
| Placental transfer | Crosses placenta in animals; likely in humans based on pharmacokinetic properties. |
| Breastfeeding | Excretion into breast milk unknown; caution in nursing mothers due to potential for adverse effects in infant. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to triamcinolone or any componentSystemic fungal infectionsIdiopathic thrombocytopenic purpura
| Precautions | Nephrotoxicity: monitor renal function and adjust dose accordingly, Ototoxicity: hearing loss may occur, especially in patients with renal impairment or those receiving high doses, Red Man Syndrome: infusion-related reaction (histamine release) can be minimized by slow infusion, Thrombophlebitis at injection site, Neutropenia, Clostridium difficile-associated diarrhea |
| Food/Dietary | Food does not significantly affect absorption of amoxicillin or probenecid, but taking with food may reduce gastrointestinal upset. Avoid alcohol for the duration of treatment due to potential disulfiram-like reaction with probenecid. |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Vanobid (corticosteroid) is classified as FDA Pregnancy Category C. In first trimester, there is potential risk of cleft palate based on animal studies; however, human data are limited. In second and third trimesters, chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm labor. Risk-benefit assessment is essential. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged therapy, assess fetal growth by ultrasound. Neonates should be monitored for adrenal insufficiency if mother received high doses near delivery. |
| Fertility Effects | Corticosteroids may delay ovulation and impair fertility by altering hypothalamic-pituitary-ovarian axis. No permanent effects on fertility documented. |
| Clinical Pearls | VANOBID is a fixed-dose combination of amoxicillin and probenecid used for treatment of uncomplicated gonorrhea (Neisseria gonorrhoeae). Probenecid increases serum levels of amoxicillin by blocking renal tubular secretion. Not first-line due to increasing resistance; Ceftriaxone plus azithromycin is preferred. Use only if cephalosporin allergy or resistance documented. Administer as a single dose with probenecid to delay excretion. |
| Patient Advice | Take this medication exactly as prescribed as a single dose. · Do not drink alcohol for at least 24 hours after taking this medication. · Complete the full course of treatment even if symptoms improve. · Inform your doctor if you are pregnant, breastfeeding, or have kidney disease. · Report any severe allergic reactions such as rash, itching, swelling, or difficulty breathing immediately. · This medication may cause diarrhea, nausea, or vomiting; contact your doctor if severe or persistent. · Avoid taking probenecid with aspirin or other salicylates as it may increase side effects. |